The A. Alfred Taubman Medical Research Institute supports some of today’s most aggressive medical science researchers, all members of the University of Michigan Medical School faculty, with three-year grants that they use to fund their investigations. 

These clinician-scientists and their laboratory teams are working to combat a wide array of diseases: childhood and adult cancer, neurodegentative diseases, diabetes, ALS, cardiovascular disease, obesity and many other debilitating conditions.

Scholars also serve as advocates for research by taking part in U-M efforts to educate the public about the importance of biomedical research and the need to provide support for scientific study.

Founding Taubman Scholars

The original Taubman Scholars, they continue to serve as leaders and advisers to the institute.

Senior Taubman Scholars

Through the progress of their research and their public stewardship of the cause of medical science, these former Taubman Scholars have earned renewed funding.

Taubman Scholars

The Taubman Scholars are senior level physician-researchers and thought leaders in discovery-driven science.

Taubman Emerging Scholars

The Emerging Scholars Program provides support for clinician-scientists on the U-M faculty who are in the early stages of their research careers.

There is a pressing need in the scientific community to do more to support early-career researchers who are increasingly choosing to leave the laboratory due to financial pressures. We are at risk of losing the next generation of our best and brightest scientists.

The Emerging Scholars Program offers an opportunity for them to establish their credentials in order to secure traditional funding in the future.  They are aggresive "high risk, high reward" scientists who already have initatied a number of human clinical trials of new therapies for disease.


Help Us Make A Difference. Make A Donation That Could Save Lives.

Make A Gift


Follow Us / Friend Us

Discovery-driven research that matters


Taubman Scholar Dr. Charles Burant tests promising diabetes drug

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

Read more

Taubman Institute leaders make the case for more doctor-scientist funding


The prestigious "Academic Medicine" journal has just published a new article authored by Taubman Institute senior management and Detroit-area attorney Scott Roberts.

The article explores the problematic gap between bench research and clinical application of new treatments or cures. 

Read more

Help Us Make A Difference. Make A Gift.

Leaders from the realms of business, academia and the community help to refine the Taubman Institute's vision, to monitor progress and to provide support, advice and counsel.

Meet the Leadership Advisory Board

Meet the Scientific Advisory Board

About Taubman Institute Video

In this video feature, Taubman Scholars explain why funding for high-risk research is so important to their work and to the discovery of promising cures and treatments.  


Stem cell surgery targets ALS Video

Patients glean hope from trial’s progress but wish it were faster


video-emerging-scholars-programDonors pitch in to keep brilliant science minds at U-M Video

Emerging Scholars program connects promising M.D.-researchers with philanthropists